The present invention relates to a 3 adrenergic receptor agonist
of formula I:
##STR1##
or a pharmaceutical salt thereof; which is capable of increasing lipolysis and
energy expenditure in cells and, therefore, is useful for treating Type 2 diabetes
and/or obesity.
